Hanmi Pharm Co Ltd
KRX:128940
Hanmi Pharm Co Ltd
KRX:128940
Price:
267 500
KRW
0.38%
Market Closed
Market Cap:
3.4T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Hanmi Pharm Co Ltd
267500
+1000 (+0.38%)
| 52 Week Range |
245 000
366 169.2238
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Hanmi Pharm Co Ltd
Balance Sheet
Balance Sheet Decomposition
Hanmi Pharm Co Ltd
Hanmi Pharm Co Ltd
| Current Assets | 721.5B |
| Cash & Short-Term Investments | 202.2B |
| Receivables | 215.2B |
| Other Current Assets | 304.1B |
| Non-Current Assets | 1.2T |
| Long-Term Investments | 159.2B |
| PP&E | 827.4B |
| Intangibles | 87.4B |
| Other Non-Current Assets | 175.7B |
| Current Liabilities | 623.5B |
| Accounts Payable | 37B |
| Accrued Liabilities | 52.7B |
| Short-Term Debt | 372.1B |
| Other Current Liabilities | 161.7B |
| Non-Current Liabilities | 268.4B |
| Long-Term Debt | 97.9B |
| Other Non-Current Liabilities | 170.5B |
Balance Sheet
Hanmi Pharm Co Ltd
Hanmi Pharm Co Ltd
Currency: KRW
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
52 471
|
138 329
|
130 372
|
47 266
|
67 338
|
106 113
|
146 157
|
209 225
|
147 329
|
54 980
|
|
| Cash Equivalents |
52 471
|
138 329
|
130 372
|
47 266
|
67 338
|
106 113
|
146 157
|
209 225
|
147 329
|
54 980
|
|
| Short-Term Investments |
45 420
|
44 197
|
199 831
|
93 119
|
31 358
|
1 979
|
1 874
|
85
|
88 212
|
199 175
|
|
| Total Receivables |
290 508
|
784 927
|
271 571
|
250 331
|
183 469
|
191 287
|
152 838
|
225 276
|
183 439
|
179 003
|
|
| Accounts Receivables |
286 172
|
777 726
|
250 515
|
247 739
|
177 851
|
185 557
|
145 243
|
222 701
|
181 579
|
176 221
|
|
| Other Receivables |
4 336
|
7 201
|
21 056
|
2 592
|
5 618
|
5 730
|
7 595
|
2 575
|
1 860
|
2 783
|
|
| Inventory |
133 069
|
158 143
|
190 381
|
232 124
|
247 755
|
326 727
|
308 538
|
250 189
|
266 185
|
288 914
|
|
| Other Current Assets |
16 251
|
19 524
|
48 587
|
35 251
|
34 173
|
36 098
|
4 965
|
19 188
|
8 994
|
8 551
|
|
| Total Current Assets |
537 719
|
1 145 121
|
840 742
|
658 091
|
564 093
|
662 204
|
614 373
|
703 962
|
694 158
|
730 624
|
|
| PP&E Net |
327 872
|
415 734
|
598 936
|
790 052
|
900 317
|
999 512
|
1 000 040
|
957 218
|
917 982
|
860 242
|
|
| PP&E Gross |
327 872
|
415 734
|
598 936
|
790 052
|
900 317
|
999 512
|
1 000 040
|
957 218
|
917 982
|
860 242
|
|
| Accumulated Depreciation |
248 149
|
268 792
|
299 731
|
325 725
|
357 172
|
383 908
|
435 110
|
517 056
|
565 260
|
634 906
|
|
| Intangible Assets |
87 862
|
67 151
|
40 068
|
45 704
|
60 690
|
66 244
|
72 886
|
80 170
|
84 587
|
81 045
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
6 218
|
9 964
|
5 927
|
17 372
|
|
| Long-Term Investments |
50 778
|
43 749
|
27 460
|
72 825
|
71 928
|
90 914
|
59 874
|
53 108
|
72 863
|
45 049
|
|
| Other Long-Term Assets |
29 103
|
50 837
|
89 765
|
94 263
|
94 181
|
94 832
|
128 635
|
132 308
|
149 069
|
164 337
|
|
| Total Assets |
1 033 335
N/A
|
1 722 593
+67%
|
1 596 971
-7%
|
1 660 934
+4%
|
1 691 210
+2%
|
1 913 706
+13%
|
1 882 027
-2%
|
1 936 729
+3%
|
1 924 586
-1%
|
1 898 668
-1%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
52 826
|
56 177
|
50 599
|
46 567
|
44 475
|
37 509
|
32 214
|
42 833
|
39 710
|
45 180
|
|
| Accrued Liabilities |
23 396
|
63 170
|
16 020
|
30 151
|
35 627
|
40 690
|
40 856
|
48 646
|
56 019
|
56 816
|
|
| Short-Term Debt |
35 556
|
37 484
|
77 418
|
170 212
|
201 500
|
213 100
|
238 100
|
255 900
|
369 100
|
336 100
|
|
| Current Portion of Long-Term Debt |
11 300
|
65 711
|
93 888
|
108 376
|
13 942
|
85 519
|
163 669
|
146 638
|
83 407
|
147 675
|
|
| Other Current Liabilities |
59 276
|
451 079
|
306 220
|
283 870
|
139 429
|
94 985
|
58 612
|
154 921
|
128 512
|
118 991
|
|
| Total Current Liabilities |
182 354
|
673 621
|
544 145
|
639 175
|
434 973
|
471 803
|
533 451
|
648 938
|
676 748
|
704 763
|
|
| Long-Term Debt |
225 357
|
264 231
|
160 915
|
197 654
|
415 751
|
552 948
|
400 419
|
301 100
|
225 816
|
89 092
|
|
| Deferred Income Tax |
2 905
|
2 909
|
2 946
|
921
|
311
|
1 571
|
452
|
0
|
0
|
0
|
|
| Minority Interest |
61 783
|
69 863
|
75 056
|
80 713
|
86 028
|
98 466
|
101 902
|
125 346
|
137 361
|
144 768
|
|
| Other Liabilities |
33 473
|
37 023
|
154 448
|
30 759
|
50 919
|
65 123
|
115 815
|
58 431
|
12 795
|
4 603
|
|
| Total Liabilities |
505 872
N/A
|
1 047 648
+107%
|
937 509
-11%
|
949 223
+1%
|
987 982
+4%
|
1 189 911
+20%
|
1 152 039
-3%
|
1 133 815
-2%
|
1 052 720
-7%
|
943 226
-10%
|
|
| Equity | |||||||||||
| Common Stock |
24 361
|
25 577
|
26 088
|
27 909
|
28 464
|
29 030
|
29 608
|
30 196
|
30 795
|
31 405
|
|
| Retained Earnings |
79 683
|
228 143
|
228 894
|
285 290
|
287 801
|
323 771
|
334 117
|
396 916
|
452 297
|
581 979
|
|
| Additional Paid In Capital |
419 009
|
417 793
|
417 282
|
415 462
|
414 906
|
414 340
|
413 763
|
413 175
|
412 575
|
411 965
|
|
| Unrealized Security Profit/Loss |
5 476
|
3 259
|
1 211
|
8 810
|
4 698
|
9 287
|
11 400
|
22 035
|
4 688
|
35 801
|
|
| Treasury Stock |
1 745
|
2 153
|
9 280
|
15 730
|
21 318
|
25 185
|
28 268
|
33 142
|
36 976
|
40 047
|
|
| Other Equity |
678
|
2 326
|
2 312
|
10 029
|
11 323
|
8 874
|
7 832
|
17 804
|
8 486
|
5 941
|
|
| Total Equity |
527 463
N/A
|
674 945
+28%
|
659 461
-2%
|
711 711
+8%
|
703 228
-1%
|
723 795
+3%
|
729 987
+1%
|
802 914
+10%
|
871 866
+9%
|
955 442
+10%
|
|
| Total Liabilities & Equity |
1 033 335
N/A
|
1 722 593
+67%
|
1 596 971
-7%
|
1 660 934
+4%
|
1 691 210
+2%
|
1 913 706
+13%
|
1 882 027
-2%
|
1 936 729
+3%
|
1 924 586
-1%
|
1 898 668
-1%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
11
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
12
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
